Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H: quinone oxidoreductase 1, in cellular systems

被引:50
作者
Dehn, DL
Siegel, D
Swann, E
Moody, CJ
Ross, D
机构
[1] Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA
[3] Univ Exeter, Sch Chem, Exeter, Devon, England
关键词
D O I
10.1124/mol.64.3.714
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The specific involvement of NAD(P) H: quinone oxidoreductase 1 (NQO1) in the bioactivation of quinone prodrugs has been shown through the use of the inhibitor of NQO1, dicoumarol. Disadvantages of using dicoumarol to inhibit NQO1 include its lack of specificity and its competitive mechanism of inhibition. The concentration of dicoumarol required for inhibition of NQO1 varies according to the substrate under evaluation, which may lead to either false conclusions of the involvement of NQO1 or the alteration of other cellular processes. We have reported previously on the chemical and biochemical properties of ES936, a mechanism-based inhibitor of NQO1 in cell-free systems. In this study, we investigated the effects of ES936 in cellular systems. ES936 ( 100 nM) inhibits more than 95% of NQO1 activity within 30 min and is stable in complete media at this concentration for a minimum of 2 h. The duration of inhibition is cell line-specific because a new protein must be generated for resumption of activity. ES936 abrogates the toxicity of streptonigrin, with greater effects seen in cell lines expressing higher levels of NQO1. ES936 does not inhibit other cellular reductases, nor does it alter cellular levels of acid-soluble thiols. Some evidence of DNA strand breaks was observed at the concentrations of ES936 required for the inhibition of NQO1 activity. From our studies, we propose the use of ES936 ( 100 nM) as a mechanism-based inhibitor of NQO1 in cellular systems and for use as a component of the routine activity assay for NQO1.
引用
收藏
页码:714 / 720
页数:7
相关论文
共 34 条
[1]  
ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548
[2]   Interaction of human NAD(P)H:Quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems [J].
Anwar, A ;
Dehn, D ;
Siegel, D ;
Kepa, JK ;
Tang, LJ ;
Pietenpol, JA ;
Ross, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (12) :10368-10373
[3]   Indolequinone antitumor agents:: Correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity [J].
Beall, HD ;
Winski, S ;
Swann, E ;
Hudnott, AR ;
Cotterill, AS ;
O'Sullivan, N ;
Green, SJ ;
Bien, R ;
Siegel, D ;
Ross, D ;
Moody, CJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (24) :4755-4766
[4]   Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin [J].
Beall, HD ;
Liu, YF ;
Siegel, D ;
Bolton, EM ;
Gibson, NW ;
Ross, D .
BIOCHEMICAL PHARMACOLOGY, 1996, 51 (05) :645-652
[5]   INCREASE OF NAD(P)H-QUINONE REDUCTASE BY DIETARY ANTIOXIDANTS - POSSIBLE ROLE IN PROTECTION AGAINST CARCINOGENESIS AND TOXICITY [J].
BENSON, AM ;
HUNKELER, MJ ;
TALALAY, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (09) :5216-5220
[6]   The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems [J].
Beyer, RE ;
SeguraAguilar, J ;
DiBernardo, S ;
Cavazzoni, M ;
Fato, R ;
Fiorentini, D ;
Galli, MC ;
Setti, M ;
Landi, L ;
Lenaz, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (06) :2528-2532
[7]   The comet assay: What can it really tell us? [J].
Collins, AR ;
Dobson, VL ;
Dusinska, M ;
Kennedy, G ;
Stetina, R .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1997, 375 (02) :183-193
[8]   HIGH-LEVELS OF EXPRESSION OF THE NAD(P)H-QUINONE OXIDOREDUCTASE (NQO1) GENE IN TUMOR-CELLS COMPARED TO NORMAL-CELLS OF THE SAME ORIGIN [J].
CRESTEIL, T ;
JAISWAL, AK .
BIOCHEMICAL PHARMACOLOGY, 1991, 42 (05) :1021-1027
[9]   Quinone reductase inhibitors block SAPK/JNK and NFκB pathways and potentiate apoptosis [J].
Cross, JV ;
Deak, JC ;
Rich, EA ;
Qian, YY ;
Lewis, M ;
Parrott, LA ;
Mochida, K ;
Gustafson, D ;
Vande Pol, S ;
Templeton, DJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (44) :31150-31154
[10]  
Ernster L., 1967, METHODS ENZYMOLOGY, VVolume 10, P309, DOI [10.1016/0076-6879(67)10059-1, DOI 10.1016/0076-6879(67)10059-1]